Researchers Submit Patent Application, "Inhibitors of Tryptases and Their Use in Treating Allergies", for Approval (USPTO 20240226076).

A patent application has been submitted for the use of tryptase inhibitors in treating allergies, asthma, and mast cell activation syndrome (MCAS). Tryptases are enzymes secreted by mast cells, and when released in excess, they can cause severe allergic reactions. The patent application specifically mentions Avoralstat as a tryptase inhibitor for these conditions. The methods involve administering the inhibitor orally or intravenously, either daily or intermittently, and may be combined with other medications such as antihistamines or corticosteroids. The patent application provides further details and can be accessed for more information. [Extracted from the article]